Image Source: AsiaOne
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancer GlobeNewswire June 11, 2024 SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients.
Source: AsiaOne